{"id":"https://openalex.org/W2890714902","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e23148","title":"Copper chelation as targeted therapy in a genetic mouse model of oncogenic BRAF-driven thyroid cancer.","display_name":"Copper chelation as targeted therapy in a genetic mouse model of oncogenic BRAF-driven thyroid cancer.","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2890714902","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e23148","mag":"2890714902"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.e23148","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e23148","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e23148","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063852242","display_name":"Mengmeng Xu","orcid":"https://orcid.org/0000-0003-3518-0550","observed_orcids":["https://orcid.org/0000-0003-3518-0550"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mengmeng Xu","raw_affiliation_strings":["Duke University Medical School, Department of Pharmacology, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical School, Department of Pharmacology, Durham, NC;","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072576684","display_name":"Danielle Elliott Range","orcid":"https://orcid.org/0000-0001-7347-0722","observed_orcids":["https://orcid.org/0000-0001-7347-0722"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Danielle Range","raw_affiliation_strings":["Duke University School of Medicine, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University School of Medicine, Durham, NC;","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039439529","display_name":"Julie Ann Sosa","orcid":"https://orcid.org/0000-0002-3356-7316","observed_orcids":["https://orcid.org/0000-0002-3356-7316"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie Ann Sosa","raw_affiliation_strings":["Duke University Medical Center, Duke Cancer Institute and Department of Surgery, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University Medical Center, Duke Cancer Institute and Department of Surgery, Durham, NC;","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4390039326"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5087099776","display_name":"Christopher M. Counter","orcid":"https://orcid.org/0000-0003-0748-3079","observed_orcids":["https://orcid.org/0000-0003-0748-3079"]},"institutions":[{"id":"https://openalex.org/I170897317","display_name":"Duke University","ror":"https://ror.org/00py81415","country_code":"US","type":"education","lineage":["https://openalex.org/I170897317"]},{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Counter","raw_affiliation_strings":["Duke University School of Medicine, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke University School of Medicine, Durham, NC;","institution_ids":["https://openalex.org/I170897317","https://openalex.org/I4210126298"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"e23148","last_page":"e23148"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9477999806404114,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10329","display_name":"Thyroid Cancer Diagnosis and Treatment","score":0.9477999806404114,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.03689999878406525,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11728","display_name":"Thyroid and Parathyroid Surgery","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/copper-chelation","display_name":"copper chelation","score":0.925000011920929},{"id":"https://openalex.org/keywords/papillary-thyroid-carcinoma","display_name":"papillary thyroid carcinoma","score":0.9309999942779541},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.9789999723434448},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6420000195503235},{"id":"https://openalex.org/keywords/genetically-engineered-mouse-models","display_name":"genetically engineered mouse models","score":0.8460000157356262},{"id":"https://openalex.org/keywords/vemurafenib","display_name":"vemurafenib","score":0.8759999871253967},{"id":"https://openalex.org/keywords/lenvatinib","display_name":"lenvatinib","score":0.9700000286102295},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mek-inhibition","display_name":"MEK inhibition","score":0.7519999742507935},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.906000018119812},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.6069999933242798},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.5839999914169312},{"id":"https://openalex.org/keywords/drug-repurposing","display_name":"drug repurposing","score":0.47099998593330383},{"id":"https://openalex.org/keywords/braf-inhibitor-resistance","display_name":"BRAF inhibitor resistance","score":0.4180000126361847}],"concepts":[{"id":"https://openalex.org/C2776131300","wikidata":"https://www.wikidata.org/wiki/Q423111","display_name":"Vemurafenib","level":4,"score":0.8696690797805786},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.8342769145965576},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7406005859375},{"id":"https://openalex.org/C2776264508","wikidata":"https://www.wikidata.org/wiki/Q6523413","display_name":"Lenvatinib","level":4,"score":0.7039862871170044},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6913522481918335},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5540590882301331},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5430802702903748},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.5278995633125305},{"id":"https://openalex.org/C2781461381","wikidata":"https://www.wikidata.org/wiki/Q2292945","display_name":"Papillary thyroid cancer","level":4,"score":0.5164349675178528},{"id":"https://openalex.org/C2779707156","wikidata":"https://www.wikidata.org/wiki/Q5611758","display_name":"Growth inhibition","level":3,"score":0.4912204146385193},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.48849713802337646},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.45557066798210144},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4112362563610077},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.38476067781448364},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.3805435597896576},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.32342979311943054},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.16880139708518982},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.14145642518997192},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.e23148","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.e23148","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.e23148","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2886296250","https://openalex.org/W2959862454","https://openalex.org/W2763277172","https://openalex.org/W2943955737","https://openalex.org/W2586911664","https://openalex.org/W2065687131","https://openalex.org/W2916655572","https://openalex.org/W2014912105","https://openalex.org/W2442862586","https://openalex.org/W3003768876"],"abstract_inverted_index":{"e23148":[0],"Background:":[1],"Over":[2],"half":[3],"of":[4,47,104,126,148,156,210,261,286,314,318],"papillary":[5],"thyroid":[6,212,263],"cancers":[7],"(PTC)":[8],"contain":[9],"the":[10,30,45,123,167,183,200,222,225,247,252,277,284],"MAPK":[11],"pathway":[12],"activating,":[13],"oncogenic":[14],"BRAF":[15,112],"V600E":[16],"mutation.":[17],"Early":[18],"clinical":[19],"trials":[20],"using":[21],"inhibitors":[22,49],"to":[23,63,70,83,101,121,207],"this":[24],"mutant":[25,111],"protein":[26],"or":[27,36],"its":[28],"substrates,":[29],"MEK1/2":[31],"kinases,":[32],"prolonged":[33],"progression-free":[34],"survival":[35],"stabilized":[37],"disease":[38,56],"in":[39,53,99,159,195,224,239,251,289,299,311,320,333],"patients":[40,62,334],"with":[41,335],"advanced":[42,336],"PTC.":[43,151,316,337],"However,":[44],"toxicities":[46,65],"these":[48,127,138,193,321],"are":[50],"uniquely":[51],"highlighted":[52],"an":[54],"indolent":[55],"like":[57],"PTC,":[58],"which":[59,161],"would":[60],"require":[61],"endure":[64],"long-term.":[66],"Our":[67],"goal":[68],"was":[69,162,179,242,273,293,302],"determine":[71],"if":[72],"tetrathimoybdate":[73],"(TM),":[74],"a":[75,142,217,312,327],"well-tolerated":[76],"copper":[77,270],"chelator":[78],"we":[79],"have":[80,208],"previously":[81],"shown":[82],"inhibit":[84,91],"BRAF-mutated":[85,131],"melanoma":[86],"via":[87],"MEK":[88],"inhibition,":[89],"can":[90],"BRAF-driven":[92,150,315],"PTC":[93,132,288,322],"growth.":[94],"Methods:":[95],"We":[96,135,191],"assessed":[97],"TM":[98,153,177,201,292,301,332],"comparison":[100],"current":[102],"standard":[103],"care":[105],"(SOC),":[106],"Lenvatinib":[107,279],"and":[108,110,169,174,280],"Sorafenib,":[109,281],"inhibitor,":[113],"Vemurafenib.":[114],"Anchorage":[115],"independent":[116],"growth":[117,158,285],"assays":[118],"were":[119,205],"used":[120],"test":[122],"inhibitory":[124],"effect":[125],"drugs":[128],"on":[129,199,203,257],"human":[130,287],"cell":[133],"lines.":[134],"then":[136],"confirmed":[137,192],"findings":[139],"by":[140,172,186,215,266],"treating":[141],"genetically":[143],"engineered":[144],"mouse":[145],"model":[146],"(GEMM)":[147],"aggressive":[149],"Results:":[152],"inhibited":[154],"57.5%":[155],"colony":[157],"vitro,":[160,300],"not":[163,243],"significantly":[164],"different":[165,245],"from":[166,221,246],"42.4%":[168],"32.2%":[170],"inhibition":[171,178,185],"Sorafenib":[173],"Lenvatinib,":[175],"respectively.":[176],"less":[180,295],"effective":[181,275,296,304],"than":[182,297],"70.3%":[184],"Vemurafenib":[187,253,298,306],"(":[188,233],"p":[189],"=0.04).":[190],"results":[194],"vivo,":[196],"where":[197,255],"mice":[198,223,256],"arm,":[202,227,254],"average,":[204],"observed":[206],"14.8%":[209],"their":[211,262],"glands":[213,264],"occupied":[214],"tumor,":[216],"statistically":[218,244],"significant":[219],"reduction":[220,238,249],"control":[226],"whose":[228],"tumor":[229,240,309],"load":[230,310],"averaged":[231],"23.6%":[232],"p=":[234],"0.008).":[235],"This":[236],"37.4%":[237],"burden":[241],"35.2%":[248],"measured":[250],"average":[258],"had":[259],"15.3%":[260],"replaced":[265],"tumor.":[267],"Conclusions:":[268],"The":[269],"chelator,":[271],"TM,":[272],"as":[274,276,303,305],"SOCs,":[278],"at":[282,307],"inhibiting":[283],"vitro.":[290],"Although":[291],"slightly":[294],"reducing":[308],"GEMM":[313],"Success":[317],"TTM":[319],"models":[323],"may":[324],"next":[325],"inform":[326],"Phase":[328],"I":[329],"trial":[330],"assessing":[331]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-09-27T00:00:00"}